Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 67,955	$ 66,886
Marketable securities, short-term	192,517	176,636
Prepaid expenses and other current assets	6,443	3,093
Total current assets	266,915	246,615
Marketable securities, long-term	20,908	62,553
Right-of-use asset	325	381
Restricted cash	235	233
Property and equipment, net	105	122
Other assets	425	221
Total assets	288,913	310,125
Current liabilities
Accounts payable	4,211	1,379
Accrued clinical trial expenses	7,027	4,387
Accrued expenses and other current liabilities	4,004	6,339
Finance lease liability, short-term	0	756
Operating lease liability, short-term	125	110
Total current liabilities	15,367	12,971
Operating lease liability, long-term	219	284
Debt, long-term	29,380	29,897
Total liabilities	44,966	43,152
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 60,079,778 and 57,910,461 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	502,313	489,453
Accumulated deficit	(258,208)	(222,798)
Accumulated other comprehensive income (loss)	(164)	312
Total stockholders’ equity	243,947	266,973
Total liabilities and stockholders’ equity	$ 288,913	$ 310,125